Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Infusion of alloreactive NK cells.
- Who it may be relevant to
- Registry conditions: Acute Myeloid Leukemia, Minimal Residual Disease, Natural Killer Cell. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Infusion of Alloreactive nk Cells for Acute Myeloid Leukemia Patients, Eligible for Allogeneic Stem Cell Transplantiation, With Persistent Minimal Residual Disease After Conventional Chemotherapy
Overview
This is a interventional, transplantation study. The procedure under study is the infusion of alloreactive NK cells in adult AML patients, eligible for ASCT, who achieved CR after conventional chemotherapy, but harbor MRD-positivity. Haploidentical KIR-L mismatched donors will be included if present at least one allele mismatch at a class I locus among the following ones: HLA-C alleles with Asn77-Lys80, HLA-C alleles with Ser77-Asn80, HLA-Bw4 alleles. KIR-L mismatched donor alloreactive NK cell repertoire will be evaluated in order to determine the functional cell dose to be used for NK cell collection. Phenotypical analysis of KIRs will be correlated to functional tests. NK cells will be selected from a steady-state large volume leukapheresis product from a suitable haploidentical KIR-ligand incompatible donor. NK cell purification will be performed if the donor leukapheresis product contains at least 10x106 NK cells/Kg. Immunomagnetic enrichment of NK cells will follow two subsequent steps: 1) depletion of CD3+ T cells followed by 2) positive selection of CD56+ NK cells. Patients will receive immunosuppressive chemotherapy, fludarabine (Flu) 25 mg/mq/ from day -5 to -3 and cyclophosphamide (Cy) 2 g/mq on day -2 (Flu/Cy). Two days after Cy administration, patients will be infused intravenously with a single dose of cryopreserved NK cells (day 0), which will be followed by subcutaneous administration of IL-2 (10 x 106 IU/day, 3 times weekly) for 2 weeks (6 doses total). PB samples will also be collected for biological studies. In particular, PB samples will be collected for molecular assessment of microchimerism and tracking of haploidentical NK cells for 30 days, immunophenotype studies, alloreactive NK cells cloning and functional assays (cytotoxicity). Enrolled patients will be followed up for at least 12 months after NK cell infusion.
Interventions
- Biological Infusion of alloreactive NK cells
Infusion of alloreactive NK cells for acute leukemia patients harboring minimal residual disease after conventional chemotherapy and prior to allogeneic stem cell transplantation
Primary outcome measures
- Safety of infusing a functional target cell dose of 2x105 alloreactive NK cells/kg in AML patients,eligible for ASCT, with persistent MRD after conventional chemotherapy [Time frame: 48 months]
- Feasibility of collecting a functional target cell dose of 2x105 alloreactive NK cells/kg in at least 70% of patients entering the study [Time frame: 48 months]
Secondary outcome measures (9)
- Number of patients who achieve and maintain MRD negativity after infusion of alloreactive NK cells [Time frame: 48 months]
- Number of patients who enter ASCT in MRD-negativity [Time frame: 48 months]
- Relapse-free survival (RFS) of patients infused with alloreactive NK cells [Time frame: 48 months]
- overall survival (OS) of patients infused with alloreactive NK cells [Time frame: 48 months]
- Assess the predictive impact of donor NK cell repertoire on overall survival [Time frame: 48 months]
- Assess the predictive impact of donor NK cell repertoire on relapse-free survival [Time frame: 48 months]
- Evaluate the microchimerism of patients receiving human NK cells [Time frame: 48 months]
- Functionally evaluate, in vitro and ex vivo, the antitumor activity of infused NK cells [Time frame: 48 months]
- Assess the molecular features of infused NK cells [Time frame: 48 months]
Eligibility criteria
Inclusion criteria
- Diagnosis of de novo or secondary AML
- Age ≥ 18 years
- Morphologic CR
- Eligibility for ASCT
- MRD-positivity after induction chemotherapy
- Availability of a KIR-L incompatible haploidentical donor
- Performance Status ≥ 70% (Karnofsky score) or ≤ 2 (WHO).
- Adequate renal (serum creatinine < 2 mg/dl), pulmonary (Sat O2 ≥ 96%) and hepatic (ALT/AST < 2.5 x N) function.
- Left Ventricular Ejection Fraction (LVEF) of >50% as determined by Echocardiogram (ECHO).
- Signed informed consent.
Exclusion criteria
- Diagnosis of AML FAB M3
- HIV positivity.
- HCV positivity with high viral load.
- Pregnant or nursing females.
- Current uncontrolled infection.
- Signs or symptoms of fluid retention (e.g. pleural effusion).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Italy · 1 center
- Antonio Curti — Bologna
Identifiers
NCT: NCT06885476 · MRD-NK